Product Information
VERQUVO 10 MG TABLET is a brand product labeled by Merck Sharp & Dohme LLC, priced at $22.7248 per EA under NDC 00006503004. Its NADAC has been published 220 times since Jul 20, 2022.
FDA first approved this application on Jan 19, 2021.
Strength
10 mg/1
Manufacturer
Merck Sharp & Dohme LLCNDC
00006503004
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VERICIGUATApproval Type
New Drug (NDA)
FDA Application
NDA214377FDA Approved
1/19/2021
On Market Since
2/1/2021
Pharmacological Classes
Price Statistics
The NADAC for VERQUVO 10 MG TABLET has been published 220 times since Jul 20, 2022, and over the history we have for it it has risen 15.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $22.7248 per EA |
|---|---|
| All-time high | $22.7579 (May 13, 2026) |
| All-time low | $19.6737 (Jul 20, 2022) |
| 52-week high | $22.7579 |
| 52-week low | $22.2046 |
| Median price | $21.5657 |
| Average price | $21.4723 |
| Largest weekly change | +5.0% (Jan 18, 2023) |
| Weeks tracked | 220 |
| Tracking since | Jul 20, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Merck Sharp & Dohme LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
vericiguat market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Soluble Guanylate Cyclase Stimulator class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VERQUVO 10 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VERQUVO 10 MG TABLET, manufactured by Merck Sharp & Dohme LLC, is $22.7248 per EA (NDC 00006503004), effective Sep 30, 2026.
How has the price of VERQUVO 10 MG TABLET changed over time?
Over the history we have for it, the NADAC for VERQUVO 10 MG TABLET has risen 15.5%. It has been tracked across 220 weekly CMS publications since Jul 20, 2022.
What are the highest and lowest recorded NADAC prices for VERQUVO 10 MG TABLET?
Since Jul 20, 2022, the NADAC for VERQUVO 10 MG TABLET has ranged from a low of $19.6737 (Jul 20, 2022) to a high of $22.7579 (May 13, 2026), with a median of $21.5657 per EA.
Are there cheaper alternatives to VERQUVO 10 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as VERQUVO 10 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures VERQUVO 10 MG TABLET?
VERQUVO 10 MG TABLET (NDC 00006503004) is labeled by Merck Sharp & Dohme LLC, and CMS classifies it as a brand product.